CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics, announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences.
The amended agreement broadens the use of CollPlant's rhCollagen, extending beyond research applications to include clinical development and commercial-scale manufacturing.
Yehiel Tal, Chief Executive Officer of CollPlant, commented, "Expanding our partnership with STEMCELL Technologies into clinical and commercial domains reflects both the evolving needs of the life sciences market and the strength of our novel technology. This milestone highlights our shared commitment to advancing safer, more effective, and sustainable solutions for researchers and biomanufacturers alike." Mr. Tal continued, "We are proud that our plant-derived rhCollagen is being chosen as a viable alternative to animal-sourced materials - an option that aligns with growing industry priorities around safety, consistency, and ethical sourcing."
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
For more information please visit http://www.collplant.com.
